Skip to Content


Artificial intelligence

AI builds momentum for smarter health care

Life sciences anticipates huge opportunities as AI helps boost targeted drug discovery, personalized health care, and more efficient production

In partnership withDataiku

The pharmaceutical industry operates under one of the highest failure rates of any business sector. The success rate for drug candidates entering capital Phase 1 trials—the earliest type of clinical testing, which can take 6 to 7 years—is anywhere between 9% and 12%, depending on the year, with costs to bring a drug from discovery to market ranging from $1.5 billion to $2.5 billion, according to Science.

AI builds momentum for smarter health care

This skewed balance sheet drives the pharmaceutical industry’s search for machine learning (ML) and AI solutions. The industry lags behind many other sectors in digitization and adopting AI, but the cost of failure—estimated at 60% of all R&D costs, according to Drug Discovery Today—is an important driver for companies looking to use technology to get drugs to market, says Vipin Gopal, former chief data and analytics officer at pharmaceutical giant Eli Lilly, currently serving a similar role at another Fortune 20 company.

“All of these drugs fail due to certain reasons—they do not meet the criteria that we expected them to meet along some points in that clinical trial cycle,” he says. “What if we could identify them earlier, without having to go through multiple phases of clinical trials and then discover, ‘Hey, that doesn’t work.’”

The speed and accuracy of AI can give researchers the ability to quickly identify what will work and what will not, Gopal says. “That’s where the large AI computational models could help predict properties of molecules to a high level of accuracy—to discover molecules that might not otherwise be considered, and to weed out those molecules that, we’ve seen, eventually do not succeed,” he says.

Download the full report.

This content was produced by Insights, the custom content arm of MIT Technology Review. It was not written by MIT Technology Review’s editorial staff.

Deep Dive

Artificial intelligence

DeepMind’s cofounder: Generative AI is just a phase. What’s next is interactive AI.

“This is a profound moment in the history of technology,” says Mustafa Suleyman.

Deepfakes of Chinese influencers are livestreaming 24/7

With just a few minutes of sample video and $1,000, brands never have to stop selling their products.

AI hype is built on high test scores. Those tests are flawed.

With hopes and fears about the technology running wild, it's time to agree on what it can and can't do.

You need to talk to your kid about AI. Here are 6 things you should say.

As children start back at school this week, it’s not just ChatGPT you need to be thinking about.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.